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Equivalent asthma control after dose reduction with
HFA-134a beclomethasone solution aerosol
H. MAGNUSSEN FOR THE COMPARATIVE INHALED STEROID INVESTIGATION GROUP (CISIG)
Krankenhaus Grosshansdorf, Zentrum fu¨r Pneumologie und Thoraxchirurgie, Grosshansdorf, Germany
Aim: The replacement of chlorofluorocarbon (CFC) by hydrofluoroalkane has the potential to improve airway
deposition of BDP. We investigated whether HFA-BDP extra-fine solution aerosol 400 mg day71 is as eective as
CFC-BDP 1000mg day71 in patients with stable, moderate asthma, having persistent bronchial hyper-
responsiveness.
Patients and Methods: One hundred and fifty patients with moderate asthma from 20 centres, on inhaled steroids
for 3 months, entered a 4-week run-in period with 1000 mg day71 CFC-BDP. Patients were then allocated to a 10-
week study phase, receiving CFC-BDP 1000mg day71 or HFA-BDP 400 mg day71. Symptom score and PEF
were measured daily and recorded as biweekly means. Spirometry, PC20FEV1, blood eosinophils and serum ECP
were determined on days 15, 29, 43 and 71, and compared to the last visit of the run-in period. All group members
were trained in a quality control centre.
Results: Treating the population of the HFA-BDP group (n=72) and the CFC-BDP group (n=78) did not show
significant dierences in terms of symptoms, lung function, airway hyperresponsiveness and serum markers of
inflammation at the end of the run-in period and the end of the study phase.
Conclusion: Using HFA instead of a CFC metered dose inhaler, containing less than half the daily dose of BDP,
allows control of symptoms and lung function parameters, without changes in bronchial hyperresponsiveness.
Key words: corticosteroids chlorofluorocarbon; hydrofluoroalkane; asthma [therapy].
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Inhaled corticosteroids are considered to be the first-line
therapy in patients with moderate to severe asthma (1),
which are often delivered by metered dose inhalers (MDI).
The propellants used to generate the aerosol are mainly
chlorofluorocarbons (CFC), which are thought to con-
tribute to the depletion of the ozone layer. Hydrofluoroalk-
ane (HFA), specifically hydrofluoroalkane 134a, has been
proposed as an alternative, chlorine-free, non-ozone-
depleting propellant. In reformulating beclomethasone
(BDP), the mean mass aerodynamic diameter can be made
significantly smaller for the HFA-BDP formulation, result-
ing in a more peripheral airway deposition, as demon-
strated by lung scintigrams (2). Data obtained by the
Andersen cascade impactor suggest that for lower dose
strengths (50–100 mg BDP), HFA-BDP generates approxi-
mately the same respirable mass at approximately half the
dose of CFC-BDP (2).Received 8 July 1999 and accepted in revised form 14 December
1999.
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0954-6111/00/060549+07 $35?00/0It has recently been shown that HFA-BDP at 400 mg
daily dose is as eective as CFC-BDP at a dose of 800 mg
day71 for the treatment of moderate asthma (3). We
performed a similar study, but measured the bronchial
hyperresponsiveness (BHR) to histamine in our study
population. The assessment of the degree of BHR was
considered to be of importance as it has been suggested that
BHR may be an additional guide for the monitoring of
corticosteroid treatment in asthmatic patients (4).
Patients and methods
PATIENTS
Patients with asthma were recruited from the practices of 18
German pneumologists, the University Hospital of Magde-
burg and Hospital Grosshansdorf.
All patients (age 18–75 years), had their asthma for at
least 3 months prior to recruitment and were on inhaled
corticosteroids for at least 3 months prior to the screening
visit. In all patients, anti-inflammatory therapy with inhaled
steroids resulted in a good control of the disease without
exacerbations in the last month. The criteria for the
diagnosis of asthma (Table 1) were collected over 24
months prior to the screening visit. In all patients, airway# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Inclusion criteria for the study population
Characteristics Allowable range
Age 18–75 years
Use of inhaled steroids BDP 1000mg
for 3 months BUD 800–1000 mg
Use of b2-agonists on demand 1 pu day71
Reversible airflow obstruction
assessed within the last 2 years
D FEV 12%
D PEF 20%
BHR to inhaled histamine PC20 FEV1 4mgml71
Baseline FEV1 60% of predicted
Variability of baseline FEV1
during run-in period
15%
BDP: Beclomethasone dipropionate; BUD: budesonide;
FEV1: forced expiratory volume in the first second;
D FEV1: change in FEV1 10min after inhalation of two
pus 2-agonist; PEF: peak expiratory flow rate; D PEF:
change in PEF 10min after inhalation of two pus
2-agonist; BHR: bronchial hyperresponsiveness.
550 H. MAGNUSSENhyperresponsiveness to inhaled histamine (PC20FEV1
4mgml71) was documented at the screening visit.
STUDY DESIGN
The study was designed as a double-blind, double-dummy,
randomized, parallel-group, multicentre study with two
treatment groups. Approval from regulatory agencies and
ethics committees was obtained for all centres. All patients
gave witnessed, written, informed consent to participate in
the study.
Patients who had passed the pre-study screening mea-
surements and fulfilled the inclusion and exclusion criteria
(Table 1) entered a 4-week run-in period. For the duration
of the run-in period all patients received beclomethasone
dipropionate at a dose of 500mg twice daily (total daily
dose 1000 mg) delivered by a breath-actuated metered dose
inhaler (Autohaler2) with a CFC propellant. Patients were
instructed in proper use of the inhaler system.
Eligible patients then entered the 10-week study phase. In
this case the clinical visit at the end of the run-in phase was
the first visit of the study period.
During the study phase the patients were randomly
assigned to receive one of the following treatments: 1000 mg
daily dose of CFC-BDP (250mg BDP/actuation) plus a
matched HFA-134a placebo Autohaler2, or a 400mg daily
dose of HFA-134a BDP (100 mg BDP/actuation) plus a
CFC-placebo Autohaler2.
DIARY CARDS
Patients filled in diary cards on a daily basis. Peak
expiratory flow was measured in the morning and theevening before medication as the best of three attempts.
The patients’ ability to perform the peak flow measure-
ments using a Mini-Wright peak-flow meter (Clement Clark
International Ltd, London, U.K.) and to record asthma
symptoms, as well as their additional therapy with inhaled 2-
agonists were assessed at the first two visits of the study phase.
Asthma symptoms during daytime (wheeze, cough,
shortness of breath, chest tightness) were each recorded
on a six-point scale, with zero representing no symptoms
and 5 representing severe symptoms. A total daily asthma
symptom score was calculated as a mean of the four
symptom scores.
Sleep disturbance was recorded separately on a five-point
scale with zero representing no symptoms and four
representing severe symptoms preventing sleep.
Asthma was defined as stable when daytime asthma
symptom score and sleep disturbance score were less than 5
or 4, respectively and the use of 2-agonist rescue
medication was less than 12 pus per 24 h, with no need
for oral glucocorticoids.
SPIROMETRY AND MEASUREMENT OF
BRONCHIAL RESPONSIVENESS
Spirometry and bronchial responsiveness to histamine were
measured at each visit, at least 6 h after withdrawal of
2-agonists. Spirometry was assessed using electronic
equipment. All measurements were documented graphically
and spirometers were calibrated prior to each measurement.
Bronchial responsiveness to histamine was measured
according to a modified protocol (5) which has shown to
yield provocation concentrations comparable to those
obtained with the standard method by Chai et al. (6).
BLOOD SPECIMENS
At each visit blood was taken from the cubital vein and
shipped to a central laboratory for determination of total
number of eosinophils and eosinophilic cationic protein
(ECP) as markers of inflammation in addition to the safety
parameters.
EVALUATION OF ASTHMA
EXACERBATIONS
An exacerbation was defined as a daytime asthma symptom
score of 5 points, a sleep disturbance score of 4 points, an
increase in supplemental use of 2-agonists of 12 pus or
more over 24 h or a decrease in peak flow of 50% or greater
from the average of the last 2 weeks of the run-in-period.
ADVERSE EVENTS
Adverse events were assessed at each visit. Type and
frequency of adverse events were noted, particularly local
side-eects within the throat. In case of clinical signs of
oropharyngeal candidiasis a candida swab test was
performed.
BDP-CFC-VS. BDP-HFA 551STANDARDIZATION AND QUALITY
CONTROL
Measurement of lung function, inhaled histamine chal-
lenges, skin testing for allergies and assessment of the
clinical asthma score were performed in each centre after
standardization and quality control by sta members of the
Hospital Grosshansdorf. The standardization procedures
were similar to the procedures developed for the European
Community Respiratory Health Survey (ECRHS) (7). The
data obtained during measurement of airway responsive-
ness were evaluated a second time in our co-ordinating
centre.
PATIENT COMPLIANCE
Compliance to the study design was defined using dierent
criteria: during the visits of the study phase the diary cards
were checked for missing items. Non-compliance was
defined as more than nine missing items observed either
during the last 14 days of run-in or the last 14 days of the
treatment period.
Compliance to the study medication was evaluated by
comparing predicted (according to the expected number of
inhaler activations) and actual inhaler canister weight with
an allowable range of +40% from the expected value.
EVALUATION OF THE EFFICACY OF THE
STUDY MEDICATION
The morning peak flow (am PEF) was considered as the
primary ecacy parameter. Evening peak flow (pm PEF),
forced expiratory volume in the first second (FEV1),
concentration of inhaled histamine causing a 20% decline
in FEV1 (PC20FEV1), frequency of 2-agonist use, daily
asthma symptom score and sleep disturbance score were
used as secondary ecacy parameters.
EVALUATION OF THE SAFETY OF THE
STUDY MEDICATION
The primary safety parameter was the report of adverse
events, secondary safety parameters were oropharyngeal
candidiasis, reported hoarseness, clinical laboratory tests
(i.e. haematology, serum chemistry, urine analysis) and
vital signs (i.e. sitting pulse rate, blood pressure, ECG).
STATISTICAL ANALYSIS OF THE EFFICACY
PARAMETERS
The mean change from baseline for am PEF was defined as
the primary response parameter. These changes were
calculated from mean PEF values during the last 2 weeks
of run-in and during the last 14 days of study treatment.
The null hypothesis of no equivalence was tested using
ANOVA with terms for treatment group, centre and
treatment group by centre interaction. The standard two
one-sided method for testing equivalence with 90%confidence intervals (CI) was used. Treatments were to be
considered equivalent if the 90% CI for the dierence
between treatments in am PEF was completely contained
within +25 lmin71. ANOVA was performed for the
secondary ecacy parameters, estimating mean treatment
dierences and 90% CI following the same method.
Results
ENROLMENT AND RETENTION
From November 1996 to October 1997 164 patients entered
the screening period. one hundred and fifty patients were
eligible for the study phase after completing the run-in-
period. Seventy-two patients were assigned to receive HFA-
BDP and 78 patients were allocated to the CFC-BDP group
(Table 2).
EFFICACY RESULTS
Lung function
The dierence between treatment groups in the mean
change from baseline for am PEF at the end of the 10-week
treatment period was 16 l min71 and therefore not
statistically significant (Fig. 1, Table 3).
Symptom scores
Overall daytime and night-time symptoms as well as 2-
agonist use were similar in both treatment groups, without
any frequent statistical significant eects of either treat-
ment.
Bronchial hyperresponsiveness
Before entering the study (screening visit) all patients
showed bronchial hyperresponsiveness to histamine (geo-
metric mean(+SEM) 053+12mgml71 for the HFA-BDP
group and 066+12mgml71 for the CFC-BDP group). At
the end of the run-in period, after 4 weeks of standardized
treatment with 1000 mg CFC-BDP, the patients allocated to
the HFA-BDP group showed a mean PC20FEV1 (+SEM)
of 069+12mgml71 and those allocated to the CFC-BDP
group showed a mean PC20FEV1(+SEM) of 064+
12mgml71. This dierence did not reach statistical
significance.
During the 10 weeks of treatment with the study
medication PC20FEV1 did not change significantly between,
or within the groups.
Markers of inflammation
The level of serum ECP and percentage of eosinophils in
the peripheral blood were increased in the majority of
TABLE 2. Characteristics of the intention-to-treat population at baseline
HFA-BDP
(n=72)
CFC-BDP
(n=78)
Sex (m/f) 22/50 30/48
Age (years)* 43 (15) 42 (15)
Atopy (%) 65.3 73.1
Duration of asthma (years)* 7.8 (6.7) 11.6 (12.1)
Symptom score{ 1.5 (0.2) 1.8 (0.24)
FEV1(l) 2.77 (0.09) 2.85 (0.09)
FEV1 (% predicted) 85.6 (1.6) 85.1 (2)
Morning PEF (l min71){ 407 (10) 414 (11)
PC20FEV1 (mg ml
71)§ 0.53 (1.18) 0.66 (1.2)
Data given as mean values (SE), except *mean values (SD) and §geometric mean (geometric SE).
{Mean of the overall daytime symptom score of the last 2 weeks of run-in period, graded from 0 for no symptoms and 5 for
incapacitating symptoms.
{Peak expiratory flow rate was measured by each patient early in the morning and the best of three attempts was recorded.
Mean value was calculated for each patient over a period of 7 days at the end of run-in.
HFA-BDP: beclomethasone dipropionate with hydrofluoroalkane propellant; CFC-BDP: beclomethasone dipropionate with
chlorofluorocarbon propellant; FEV1: forced expiratory volume in the first second; PEF: Peak expiratory flow rate;
PC20FEV1: provocative concentration of histamine causing a 20% fall in FEV1.
FIG 1. Time course of ecacy parameters during the study phase. (a) Symptom score: assessed as the mean of the overall
daytime symptom score from the last 2 weeks, graded from 0 for no symptoms to 5 for incapacitating symptoms (+SD) (b)
am PEF: peak expiratory flow rate, measured in the morning as the best of three attempts. Mean values were calculated for
each patient over a 2-week period (+SD). (c) FEV1: forced expiratory volume in the first second (+SD). (d) PC20FEV1:
provocative concentration causing a 20% fall in FEV1 values, given as geometric means (SEM). –~–HFA-BDP; –&–CFC-BDP.
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TABLE 3. Summary of lung function data (FEV1, am PEF, pm PEF) airway responsiveness (PC20FEV1) and markers of
inflammation (eosinophils, ECP)
After run-in period After treatment period
HFA-BDP CFC-BDP HFA-BDP CFC-BDP
FEV1 (l) 277 (009) 285 (009) 275 (009) 28 (01)
PEF am (lmin71) 407 (10) 414 (11) 410 (10) 413 (11)
PEF pm (lmin71) 417 (10) 421 (11) 415 (10) 422 (11)
PC20 FEV1 (mgml
71){ 053 (118) 066 (12) 063 (12) 0.7 (12)
Eosinophils (%)* 53 (38) 47 (31) 43 (42) 43 (28)
ECP (g l71)* 154 (81) 163 (123) 164 (104) 166 (117)
Data are given as mean (SE), { geometric mean (geometric SE) and *mean (SD).
HFA-BDP: Beclomethasone dipropionate with hydrofluoroalkane propellant; CFC-BDP: beclomethasone dipropionate with
chlorofluorocarbon propellant; FEV1: forced expiratory volume in the first second; PEF: peak expiratory flow rate, measured
in the morning (am) or in the evening (pm). The best of three attempts was recorded. Mean value was calculated for each
patient over a period of 14 days at the end of run-in and the last 14 days of the study phase respectively; PC20FEV1:
provocative concentration of histamine causing a 20% fall in FEV1; ECP: eosinophil cationic protein.
BDP-CFC-VS. BDP-HFA 553patients. However, day 71 mean values revealed a slight,
but not significant, decrease in eosinophils for the HFA-
BDP-treated patients (Table 4). There was no significant
dierence between the treatment groups.
SAFETY RESULTS
Asthma exacerbations
Throughout the entire study period no asthma exacerba-
tions occurred that met the above-mentioned criteria.
Adverse events
Analysis of reported adverse events (AE) did not reveal any
significant dierences between the treatment groups, nor
for systemic or local side-eects (HFA-BDP group 83%,
CFC-BDP group 77%). Specifically, candidiasis occurred
to a similar degree in both treatment groups (HFA-BDP
group 28%, CFC-BDP group 26%).
Compliance
Compliance to the application of the study medication was
good, as more than 85% of patients in both treatment
groups had predicted canister weight values. One patient in
the HFA group and six patients in the CFC group did not
complete the diary cards suciently, but all other data on
these patients were available.
As there was no statistically significant dierence
between the intention-to-treat population and the compli-
ant-completers population, we report on the intention-to-
treat population only.Discussion
This study demonstrated that a reduction of the daily dose
of inhaled beclomethasone dipropionate in patients with
moderate, persistent asthma can be performed safely when
CFC propellants are replaced by HFA-134a in a solution
formulation with extra-fine particles. There was no evidence
for a loss of asthma control over a time period of 10 weeks.
We enrolled patients with moderate persistent asthma
according to the GINA classification of pretreated asth-
matics (1). Moderate, persistent asthma was diagnosed by
the physicians of the participating centres on the basis of
symptoms, lung function and peak flow variability, before
initiating corticosteroid treatment. To verify the presence of
the asthmatic disease even in a patient with a low daily
asthma symptom score and normal lung function, demon-
stration of bronchial hyperresponsiveness at the screening
visit, was part of our inclusion criteria (Table 1).
As in most asthmatic patients on inhaled corticosteroids
the presence of bronchial hyperresponsiveness was more
common than symptoms and impaired lung function (8).
Because we chose the cut-o between normal and increased
bronchial responsiveness at 40mg ml71 rather than
80mg ml71 (9–11), we felt to have appropriately
documented asthmatic airway disease in our study
population.
To standardize the methodology between centres, we
performed a training programme in the Hospital Gros-
shansdorf using an approach similar to the European
Community Respiratory Health Survey (7) and Drazen
et al. (12). All centres were provided with nebulizers,
histamine solution and any additional equipment necessary
for the measurement of bronchial responsiveness. Further-
more, as part of our quality control programme, centres
were visited by experienced sta to ensure strict application
of the protocol. All data collected by the centres were
reevaluated at Hospital Grosshansdorf. Using this quality
TABLE 4. Summary of symptom scores and rescue medication
After run-in period After treatment period
HFA-BDP CFC-BDP HFA-BDP CFC-BDP
Overall daytime symptom score{ 151 (019) 177 (024) 157 (024) 179 (035)
Wheeze* 026 (005) 043 (007) 025 (006) 049 (011)
Cough* 054 (008) 053 (008) 043 (007) 051 (01)
Shortness of breath* 045 (008) 053 (009) 053 (009) 053 (011)
Chest tightness* 026 (006) 029 (006) 036 (008) 025 (008)
Sleep disturbance score{ 032 (006) 032 (006) 035 (007) 037 (009)
2-rescue medication (pus day
71) 165 (023) 208 (023) 163 (024) 21 (03)
Data given as mean values (SE). {Mean of the overall daytime symptom score from the last 2 weeks of run-in and the last 2
weeks of the study phase respectively, graded from 0 for no symptoms and 5 for incapacitating symptoms.
*Mean score for daytime symptoms from the last 2 weeks of run-in and the last 2 weeks of the study phase respectively,
graded from 0 for no symptoms and 5 for incapacitating symptoms.
{Mean of the sleep disturbance score from the last 2 weeks of run-in and the last 2 weeks of the study phase respectively,
graded from 0 for no symptoms and 4 for symptoms preventing from sleep.
HFA-BDP: Beclomethasone dipropionate with hydrofluoroalkane propellant;
CFC-BDP: beclomethasone dipropionate with chlorofluorocarbon propellant.
554 H. MAGNUSSENcontrol programme, we provided evidence that the data
from the dierent centres were comparable.
To minimize the intra-individual variation due to
inhalation techniques, we used the Autohaler2 System in
both treatment arms of the study.
In this study we compared two therapeutic regimens
containing inhaled corticosteroids during a 10-week study
period and found no significant dierence between the two
study populations. Therefore an important question
challenging our study protocol refers to the length of the
study period.
It has been shown that during reduction or cessation of
inhaled corticosteroids symptoms reappear and lung func-
tion (FEV1 or PEF) deteriorate dependent on the degree of
bronchial hyperresponsiveness under treatment (13,14). In
a group of asthmatics treated for more than 1 year with
inhaled corticosteroids, we demonstrated that the reoccur-
rence of symptoms and lung function impairment in
patients with a PC20FEV151mg ml
71 was observed within
a few days to weeks (14). These data are in line with the
results of studies investigating the eects of cessation of
short-term corticosteroid treatment (15–20), whereas in those
asthmatic subjects having PC20FEV1 levels41mg ml
71
clinical and functional consequences of cessation of inhaled
steroid therapy did not occur within 6 weeks (14).
As in the present study, the mean PC20FEV1 value to
inhaled histamine was less than 1mg ml71, a study period
of 10 weeks should have been sucient to observe a loss of
control of asthma, if the therapeutic eect of 400 mg daily
dose of HFA-BDP had been markedly lower than that of a
daily dose of 1000mg CFC-BDP. Our interpretation is also
supported by the observations of Juniper et al. (13), who
were unable to demonstrate an impairment of bronchial
hyperresponsiveness after cessation of inhaled steroids, in an
asthmatic population who had a PC20FEV141mg ml
71
during inhaled steroid therapy.It has recently been demonstrated that an increase in the
dose of inhaled corticosteroids results in an improvement in
BHR in patients with optimized symptom control and
stable lung function (4). This observation indirectly
supports our interpretation as a decrease of BDP using
HFA as propellant did not increase bronchial responsive-
ness.
In summary, our study confirms the observation (3,21),
that HFA-BDP with extra-fine particles at a dose of less
than half compared to CFC-BDP, is sucient for symptom
control and stable lung function.
This is the first study demonstrating that bronchial
hyperresponsiveness remains stable despite a decrease in
BDP dose.
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